Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.

GSK (GSK) announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary endpoint of PFS ...

GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line ...

This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

The market value of Zai Lab has not appreciated considerably since my "Hold" sentiment. Check out why I'm transitioning from ...

Dec 20 (Reuters) - GSK (GSK.L), opens new tab said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in ...